Clinical reference Biomarker Directory
Back to directory

Vasoactive intestinal polypeptide

Emerging

VIP excess causes VIPoma, a rare pancreatic tumor syndrome with severe watery diarrhea and low potassium.

Also known as VIP vasoactive intestinal peptide
In plain language

VIP is a gut hormone, and too much of it causes a rare tumor syndrome with severe watery diarrhea and low potassium. High VIP levels combined with these specific symptoms point doctors toward this diagnosis, and surgery or a symptom-controlling drug are the main treatments.

Biomarker & context

Vasoactive intestinal polypeptide (VIP) is a gut hormone that regulates intestinal secretion and motility; its excess causes a rare and distinctive clinical syndrome.

What it indicates

Markedly elevated VIP causes VIPoma (Verner-Morrison syndrome), a rare pancreatic neuroendocrine tumor producing profuse watery diarrhea, hypokalemia, and low stomach acid, sometimes called "WDHA syndrome" (watery diarrhea, hypokalemia, achlorhydria).

Diagnosis & clinical testing

Markedly elevated VIP alongside this classic clinical triad supports diagnosis, followed by tumor localization imaging (CT, MRI, or somatostatin receptor imaging) to guide surgical planning.

Guiding treatment

Surgical resection is the primary treatment when the tumor is localized and resectable; octreotide (a somatostatin analog) can control the severe diarrhea symptoms in unresectable or metastatic disease, similar to symptom management approaches used for other functional neuroendocrine tumors discussed in this biomarker set.

Clinical significance

Diagnosis combines elevated VIP with the classic watery diarrhea/hypokalemia/achlorhydria clinical triad.

References
  1. General endocrine oncology reference literature on VIPoma/Verner-Morrison syndrome diagnosis and management.